Abstracts tagged "Magnetic resonance imaging (MRI)"

Abstract Number: 0683 • ACR Convergence 2024
Prognostic Value of Systemic Sclerosis-associated Primary Heart Involvement
Caya Gharibian¹, Vanessa Lupi¹, Alexander Gotschy¹, Mike Becker², Rucsandra Dobrota¹, Muriel Elhai³, Sinziana Muraru¹, Suzana Jordan¹, Anna-Maria Hoffmann-Vold⁴, Oliver Distler⁵, Robert Manka¹, Cosimo Bruni¹ and Carina Mihai¹, ¹University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ³University Hospital zurich, Zürich, Switzerland, ⁴Oslo University Hospital, Oslo, Norway, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: A definition of primary heart involvement (pHI) in systemic sclerosis (SSc) was recently developed (Bruni C et al. J Scleroderma Relat Disord. 2022;7:24-32). Cardiac…
Abstract Number: 1635 • ACR Convergence 2024
Magnetic Resonance Imaging for Therapy Monitoring in Giant Cell Arteritis – Impact on Disease Management
Matthias Froehlich¹, Michael Gernert², Marc Schmalzing³, Patrick-Pascal Strunz⁴, Hanna Labinsky⁵, Thorsten A. Bley⁶ and Konstanze V. Guggenberger⁶, ¹Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, ²Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, ³University Hospital Wuerzburg, Würzburg, Germany, ⁴University hospital of Wuerzburg, Wuerzburg, Germany, ⁵University Hospital Würzburg, Wuerzburg, Germany, ⁶University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Imaging techniques such as magnetic resonance imaging (MRI) are a cornerstone for the diagnosis of giant cell arteritis (GCA). In the further course of…
Abstract Number: 0689 • ACR Convergence 2024
Arrhythmic Burden, Myocardial Markers, and Long-term Survival in Distinct Cardiac Magnetic Resonance Subsets of Systemic Sclerosis
Silvia Laura Bosello¹, Enrico De Lorenzis², Giacomo De Luca³, Antonio Tonutti⁴, veronica Batani⁵, Pier Giacomo Cerasuolo⁶, Gerlando Natalello⁷, Lucia Lanzo⁶, Gabriella Alonzi⁶, Silvia Fiore⁶, Stefano Di Murro⁶, Andrea Zoli⁶, Valentina Boni⁶, Riccardo Marano⁸, Francesca Augusta Gabrielli⁹, Francesco Del Galdo¹⁰, Dan Knight¹¹, Vivek Muthurangu¹¹, Christopher Denton¹², Maria De Santis⁴, Marco Matucci Cerinic⁵ and Maria Antonietta D'Agostino¹³, ¹Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²Catholic University of the Sacred Heart, Roma, Rome, Italy, ³Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ⁴Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Italy, ⁵Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ⁶Division of Rheumatology, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ⁸Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Diagnostic Imaging Area, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, ⁹Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹⁰University of Leeds, Leeds, United Kingdom, ¹¹UCL Department of Cardiac MRI, University College London (Royal Free Campus), London, United Kingdom, ¹²University College London, Northwood, United Kingdom, ¹³Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Cardiac involvement in Systemic Sclerosis (SSc) is widely recognized as heterogeneous and, when clinically evident, it is associated with a poor prognosis. Recently, five…
Abstract Number: 1757 • ACR Convergence 2024
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
Walter Maksymowych¹, Sofia Ramiro², Denis Poddubnyy³, Xenofon Baraliakos⁴, Robert Lambert¹, Ute Massow⁵, Thomas Vaux⁶, Chetan Prajapati⁶, Alexander Marten⁵, Natasha de Peyrecave⁷ and Mikkel Ostergaard⁸, ¹University of Alberta, Edmonton, AB, Canada, ²Leiden University Medical Center, Bunde, Netherlands, ³Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: The impact of bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, on structural lesions in patients (pts)…
Abstract Number: 0696 • ACR Convergence 2024
MRI DAVIX Index Is an Imaging Biomarker for Endothelial Damage of Systemic Sclerosis Digital Ulcers
Stefano Di Donato¹, Rebecca Ross², Yassir El-Sherbiny³, Riccardo Bixio⁴, Marco Minerba⁵, Christopher Wasson⁶, Jun Li⁷, Jochen SCHMITZ⁸, Sudha Visvanathan⁹ and Francesco Del Galdo⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Medicine and Health, University of Leeds, Leeds, United Kingdom, ³Nottingham Trent University, Nottingham, United Kingdom, ⁴University of Verona, Verona, Verona, Italy, ⁵1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2. NIHR Leeds Biomedical Research Centre, United Kingdom, Leeds, United Kingdom, ⁶University of Leeds, Leeds, United Kingdom, ⁷Boehringer Ingelheim, Danbury, CT, ⁸Boehringer-Ingelheim, Ridgefield, CT, ⁹Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT
Background/Purpose: Circulating endothelial cells (CEC) and their precursors have been shown to correlate to the severity of vascular manifestations in Systemic sclerosis1, such as Digital…
Abstract Number: 1957 • ACR Convergence 2024
Assessing Left Ventricular Hemodynamic Forces in Systemic Sclerosis Patients: Pilot Study
Aïcha Kante¹, Andreea Afana², Damien Sène³, Valérie Bousson⁴, Trecy Goncalves⁵, Edouard Ballout⁵, Solenn Toupin⁵, Jean-Guillaume Dillinger⁶, William Bigot³, Valentin Pagis⁷, Karine Champion³, Ruxandra burlacu⁷, stephane mouly³, Patrick Henry⁶, Theo Pezel⁶ and Cloé Comarmond³, ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ²Department of Cardiology, University of Medicine and Pharmacy Craiova, Craiova, Romania, ³Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ⁴Department of Radiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, ⁵Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, France, ⁶Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, ⁷Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease marked by inflammation, microvascular changes and fibrosis. Cardiac comorbidities are the leading cause of mortality. Early…
Abstract Number: 1038 • ACR Convergence 2023
Improved Assessment of Structural Damage in the Spine in Patients with Axial Spondyloarthritis by MRI-based Synthetic CT: A Comparison with Low-dose CT and X-ray
Simone Tromborg Willesen¹, Nora Vladimirova¹, Jakob Moeller², Anna Enevold Fløistrup Hadsbjerg¹, Bimal Mayur Kumar Vora³, Sengul Seven¹, Susanne Juhl Pedersen¹ and Mikkel Østergaard¹, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ²Herlev-Gentofte Hospital, Herlev, Denmark, ³Singapore General Hospital, Singapore, Singapore
Background/Purpose: Whether a therapy has bone structure-modifying effects in the spine is crucial to determine since this is a prerequisite for a therapy to reduce…
Abstract Number: 1866 • ACR Convergence 2023
MRI Confirms MRE Evidence of Sacroiliitis in Many with Crohn’s Disease: A Prospective Study for the Screening of axSpA in High-risk Populations
Fardina Malik¹, Soterios Gyftopoulos¹, Jordan Axelrad¹, Shannon Chang¹, Simon Hong¹, Maia McAllister², Morayo Kendra Olateru Olagbegi³, Erin Alaia¹, William Walter¹, Accelerating Medicines Partnership Program RA SLE Network⁴, David Hudesman¹ and Jose Scher⁵, ¹NYU Grossman School of Medicine, New York, NY, ²NYU, New York, NY, ³New York University, New York, NY, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Sacroiliitis can be detected incidentally on magnetic resonance enterography (MRE) scans in Crohn's disease (CD) patients, obtained for CD assessment during clinical practice. However,…
Abstract Number: 2203 • ACR Convergence 2023
Self-Reported and Physician´s Assessment of Inflammatory Back Pain According to ASAS Criteria: Is It the Same?
Diego Benavent¹, Mar Tapia², Daniel Bernabeu², Victor muley², Chamaida Plasencia-Rodríguez³, Alejandro Balsa³ and Victoria Navarro-Compán⁴, ¹Hospital la Paz, Madrid, Spain, ²Radiology Department, Hospital La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain
Background/Purpose: Inflammatory back pain (IBP) is the core symptom in patients with axial spondyloarthritis (axSpA). For its assessment, experts recommend using the Assessment of SpondyloArthritis…
Abstract Number: 1041 • ACR Convergence 2023
Efficacy of Apremilast on Peripheral and Axial Inflammation in Patients with Psoriatic Arthritis Based on Whole-Body Magnetic Resonance Imaging
Mikkel Østergaard¹, Mikael Boesen², Walter P. Maksymowych³, Robert Lambert⁴, Guillermo Valenzuela⁵, Michael Bubb⁶, Olga Kubassova⁷, Jyotsna Reddy⁸, Stephen Colgan⁹, Yuri Klyachkin¹⁰, Cynthia Deignan¹¹, Zhenwei Zhou⁸ and Philip J. Mease¹², ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ²Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶University of Florida, Gainesville, FL, ⁷Image Analysis Group, Philadelphia, PA, ⁸Amgen, Inc., Thousand Oaks, CA, ⁹Amgen, Inc., Halton Hills, ON, Canada, ¹⁰Amgen, Inc., Lexington, KY, ¹¹Amgen, Inc., Agoura Hills, CA, ¹²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Apremilast is an oral phosphodiesterase 4 inhibitor with a unique immunomodulatory mechanism of action and is approved for the treatment of psoriatic arthritis (PsA).…
Abstract Number: 1868 • ACR Convergence 2023
Long-term Efficacy of a 2-year MRI Treat-to-target Strategy on Radiographic Joint Damage Progression in Rheumatoid Arthritis Patients in Clinical Remission – Five Year Follow-up of the IMAGINE-RA Randomized Clinical Trial
Signe Møller-Bisgaard¹, Kim Hørslev-Petersen², Lykke Ørnbjerg¹, Bo Ejbjerg³, Merete L Hetland¹, Jakob Moeller⁴, Robin Christensen⁵, Sabrina Mai Nielsen⁶, Daniel Glinatsi⁷, Mikael Boesen⁸, Kristian Stengaard-Pedersen⁹, Ole Rintek Madsen¹⁰, Bente Jensen¹¹, Jan Alexander Villadsen², Ellen-Margrethe Hauge⁹, Oliver Hendricks², Hanne Merete Lindegaard¹², Niels Steen Krogh¹³, Anne Grethe Jurik⁹, Henrik Thomsen⁴ and Mikkel Østergaard¹⁴, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ³Slagelse Hospital, Slagelse, Denmark, ⁴Herlev-Gentofte Hospital, Herlev, Denmark, ⁵Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ⁶The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁷Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Sweden, ⁸Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, ⁹Aarhus University Hospital, Aarhus, Denmark, ¹⁰Herlev-Gentofte Hospital, Gentofte, Denmark, ¹¹Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ¹²Odense Hospital, Odense, Denmark, ¹³ZiteLab ApS, Frederiksberg, Denmark, ¹⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Radiographic joint damage progresses in 20-30% of rheumatoid arthritis (RA) patients despite fulfilling clinical remission criteria (1). Osteitis assessed on MRI is a well…
Abstract Number: 2422 • ACR Convergence 2023
Magnetic Resonance Imaging Reflects Disease Activity in the “Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab” Trial (The GUSTO Trial)
Lisa Christ¹, Harald Bonel², Jennifer Cullmann³, Luca Seitz⁴, Lukas Butikofer⁵, Franca Wagner⁶ and Peter Villiger⁷, ¹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ²Department of Diagnostic, Interventional and Pediatric Radiology (DIPR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Campusradiologie, Lindenhofspital Bern, Bern, Switzerland, ³Campusradiologie, Lindenhofspital Bern, Bern, Switzerland, ⁴Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ⁵CTU Bern, University of Bern, Bern, Switzerland, Bern, Switzerland, ⁶University Institute of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland, ⁷Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland
Background/Purpose: Magnetic resonance imaging (MRI) is well established for diagnosing giant cell arteritis (GCA). Its role in monitoring disease activity has yet to be determined.…
Abstract Number: 1162 • ACR Convergence 2023
Serial Imaging Changes in Skeletal Muscle Composition and Their Association with Clinical Outcomes in Idiopathic Inflammatory Myopathies
Mamatha Gorijavolu¹, Chengappa Kavadichanda¹, Ramesh Ananthakrishnan¹, Christina Mariaselvam¹, Molly Thabah¹ and VS Negi², ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²All India Institute of Medical Sciences, Bilaspur, Puducherry, India
Background/Purpose: Muscle weakness in inflammatory myopathies (IIM) is due to muscle-edema, atrophy and fatty-infiltration among which edema is the predominant cause at baseline. Some IIM…
Abstract Number: 1870 • ACR Convergence 2023
Assessing the Appropriateness of Imaging Modalities in Primary Care for Low Back Pain and Their Impact on Outcomes: A Retrospective Observational Study in a Single Center in Trenton
Damira Sereda¹, Cristine Arcilla², Kudret Arslan³ and Daniel Goldsmith⁴, ¹Capital Health Medical Canter, Trenton, NJ, ²Capital Health Regional Medical Center, Ewing Township, NJ, ³Capital Health Medical Center, Trenton, NJ, ⁴Capital Health Regional Medical Center, Trenton, NJ
Background/Purpose: Low back pain (LBP) is a leading cause of doctor visits and disability. The annual direct expenditures for LBP management exceed $80 billion, not…
Abstract Number: 2549 • ACR Convergence 2023
Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT
Walter P. Maksymowych¹, Robert Lambert², Eswar Krishnan³, Baojin Zhu³, Rebecca Bolce³ and Mikkel Østergaard⁴, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: The effect of Ixekizumab (IXE) on structural lesions in the sacroiliac joints (SIJ) of patients (pts) with radiographic Axial Spondylarthritis (r-axSpA) assessed by magnetic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.